Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 64.25M |
| Revenue (ttm) | 1.88M |
| Net Income (ttm) | -30.09M |
| Shares Out | 3.72M |
| EPS (ttm) | -10.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $16.54 |
| Previous Close | $16.98 |
| Change ($) | -0.44 |
| Change (%) | -2.59% |
| Day's Open | 17.15 |
| Day's Range | 16.12 - 17.15 |
| Day's Volume | 28,954 |
| 52-Week Range | 4.66 - 25.67 |
News
With the trading day about half over, the broad markets had pulled back on Monday.
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics...
About VRDN
Viridian Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found... [Read more...]
| Industry Biotechnology | Founded 2006 |
| CEO William Marshall | Employees 45 |
| Stock Exchange NASDAQ | Ticker Symbol VRDN |
Financial Performance
In 2019, VRDN's revenue was $4.46 million, a decrease of -46.80% compared to the previous year's $8.39 million. Losses were -$41.87 million, 28.0% more than in 2018.